Economic impact of subclinical mastitis treatment in early lactation using intramammary nisin

• Published in: Journal of dairy science Vol. 107; no. 7; pp. 4634 - 4645
• Main Authors: Rodriguez, Zelmar, Cabrera, Victor E., Hogeveen, Henk, Ruegg, Pamela L.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2024; Elsevier
• Subjects: Animals; Anti-Bacterial Agents - economics; Anti-Bacterial Agents - therapeutic use; Cattle; Dairying - economics; Female; Lactation; Mastitis, Bovine - drug therapy; Mastitis, Bovine - economics; Milk; nisin; Nisin - economics; Nisin - therapeutic use; subclinical mastitis; treatment cost; treatment cost; nisin; subclinical mastitis
• ISSN: 0022-0302; 1525-3198; 1525-3198
• DOI: 10.3168/jds.2023-24311

The list of standard abbreviations for JDS is available at adsa.org/jds-abbreviations-24. Nonstandard abbreviations are available in the Notes. Treatment of subclinical mastitis (SCM) during lactation is rarely recommended due to concerns related to both antimicrobial usage and the costs associated with milk discard. Nisin is a naturally produced antimicrobial peptide with a gram-positive spectrum that, when given to dairy cows, does not require milk discard. We evaluated the economic impact of the treatment of SCM during early lactation using a nisin-based intramammary treatment under different scenarios that included various treatment costs, milk prices, and cure rates. We stochastically simulated the dynamics of SCM detected during the first week of lactation. The net economic impact was expressed in US dollars per case. The probabilities of an event and their related costs were estimated using a model that was based on pathogen-specific assumptions selected from peer-reviewed articles. Nisin cure rates were based on results of pivotal studies included in the US Food and Drug Administration (FDA) approval submission. Based on our model, the average cost of a case of intramammary infection (i.e., only true-positive cases) in early lactation was $170 (90% = $148–$187), whereas the cost of a clinical mastitis case was $521 (90% range = $435–$581). Both estimates varied with etiology, parity, and stage of lactation. When comparing the net cost of SCM cases (i.e., CMT-positive tests) detected during the first week of lactation, nisin treatment generated an average positive economic impact of $19 per CMT-positive case. The use of nisin to treat SCM was beneficial 93% of the time. Based on the sensitivity analysis, treatment would result in an economically beneficial outcome for 95% and 73% of multiparous and primiparous cows, respectively. At the herd level, use of intramammary nisin to treat SCM in cows in early lactation was economically beneficial in most tested scenarios. However, the economic impact was highly influenced by factors such as rate of bacteriological cure, cost of treatment, and parity of the affected animal. These factors should be considered when deciding to use nisin as a treatment for SCM.